No Need Yet To Adapt Pfizer Vaccine For Covid Variants: BioNTech Chief
"It is quite possible that in the next six to 12 months, further variants will emerge and that would require adaptation of the vaccine but it is at the moment not yet the case," Ugur Sahin said.
The first generation vaccine developed by BioNTech-Pfizer works against coronavirus variants such as the Delta strain and does not need to be modified for the moment, the chief executive of German company BioNTech said Monday.
"It is quite possible that in the next six to 12 months, further variants will emerge and that would require adaptation of the vaccine but it is at the moment not yet the case," Ugur Sahin told journalists.
A decision to make a switch should be made only if it is clear that the vaccine failed to work or is only offering sub-par protection against the virus.
The fast-changing situation meant that getting the timing for the change right was also crucial.
"Making a decision at the moment might turn out to be wrong in three or six months if another variant is dominating. Therefore the timing of the decision must be appropriate," he said.
"At the moment we have a good understanding that the booster vaccine with the parental strain is completely sufficient," stressed Sahin.
BioNTech's partner Pfizer has also repeatedly amplified the case for booster shots amid the latest wave of infections.
Countries including France and Germany have said they will begin offering the additional shot to the elderly and the most vulnerable from September.
BioNTech-Pfizer have shipped around one billion doses of their vaccines to more than 100 countries or territories around the world.
They are expecting their annual manufacturing capacity to reach three billion doses by year's end, before climbing to four billion doses in 2022.
"It is quite possible that in the next six to 12 months, further variants will emerge and that would require adaptation of the vaccine but it is at the moment not yet the case," Ugur Sahin told journalists.
A decision to make a switch should be made only if it is clear that the vaccine failed to work or is only offering sub-par protection against the virus.
The fast-changing situation meant that getting the timing for the change right was also crucial.
"Making a decision at the moment might turn out to be wrong in three or six months if another variant is dominating. Therefore the timing of the decision must be appropriate," he said.
"At the moment we have a good understanding that the booster vaccine with the parental strain is completely sufficient," stressed Sahin.
BioNTech's partner Pfizer has also repeatedly amplified the case for booster shots amid the latest wave of infections.
Countries including France and Germany have said they will begin offering the additional shot to the elderly and the most vulnerable from September.
BioNTech-Pfizer have shipped around one billion doses of their vaccines to more than 100 countries or territories around the world.
They are expecting their annual manufacturing capacity to reach three billion doses by year's end, before climbing to four billion doses in 2022.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
